VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

8295	Companies
114846	Keywords
55288	Articles
62438	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 10/03/2024 at 07:00, 1 month 18 days ago

Valneva organise une journée investisseurs à New York le 10 octobre 2024
Valneva organise une journée investisseurs à New York le 10 octobre 2024 pour présenter son portefeuille de vaccins contre des maladies infectieuses. Événement en présentiel et retransmis en direct

Valneva Vaccins Journée Investisseurs Maladies Infectieuses NY
PRESS RELEASE

published on 10/03/2024 at 07:00, 1 month 18 days ago

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
Valneva SE to host Investor Day at Lotte New York Palace Hotel on Thursday, October 10, 2024, focusing on R&D pipeline and revenue-generating vaccines

Investor Day Valneva SE Vaccine R&D Pipeline Lotte New York Palace Hotel
PRESS RELEASE

published on 09/24/2024 at 11:01, 1 month 27 days ago

Original-Research: Valneva (von First Berlin Equity Research GmbH): Kaufen
First Berlin Equity Research GmbH hat ein Research Update zu Valneva SE veröffentlicht, die Kaufempfehlung bestätigt und das Kursziel herabgesetzt. Analyse umfasst finanzielle Situation und Ausblick abhängig von Einnahmen aus dem Lyme-Impfstoff

Research Update Kursziel Kapitalerhöhung Valneva Aktienempfehlung
BRIEF

published on 09/23/2024 at 15:51, 1 month 27 days ago

Valneva renforce son capital grâce à une augmentation de capital dans le cadre d'une concentration stratégique sur le développement de vaccins

Valneva SE Développement De Vaccins Acheter Une Note Recherche Sur Les Actions Levée De Capitaux
BRIEF

published on 09/23/2024 at 15:51, 1 month 27 days ago

Valneva Bolstered by Capital Raise Amid Strategic Focus on Vaccine Development

BUY Rating Valneva SE Vaccine Development Equity Research Capital Raise
PRESS RELEASE

published on 09/23/2024 at 15:46, 1 month 27 days ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Valneva SE (FR0004056851) with a BUY rating and a decreased price target to €7.70, reflecting the recent capital raise completed on 13 September 2024

BUY Rating Price Target Valneva SE Equity Research Capital Raise
BRIEF

published on 09/23/2024 at 10:59, 1 month 28 days ago

Bpifrance franchit en baisse le seuil de 10% des droits de vote de VALNEVA

Capital Franchissement De Seuil AMF Valneva Bpifrance
BRIEF

published on 09/23/2024 at 10:59, 1 month 28 days ago

Bpifrance crosses the threshold of 10% of VALNEVA voting rights downwards

Capital AMF Valneva Threshold Crossing Bpifrance
BRIEF

published on 09/23/2024 at 10:58, 1 month 28 days ago

Franchissement de Seuil chez VALNEVA SE par Bpifrance

Capital Franchissement De Seuil Valneva CDC Bpifrance
BRIEF

published on 09/23/2024 at 10:58, 1 month 28 days ago

Threshold Crossing at VALNEVA SE by Bpifrance

Capital Valneva CDC Threshold Crossing Bpifrance

Accesswire

Published on 11/21/2024 at 10:03, 1 hour 28 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 31 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 31 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 56 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 11 hours 6 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:01, 30 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 31 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 34 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 1 minute ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 1 hour 26 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 33 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 23 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 11 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE